

*Matters to be Considered:* The open session of the meeting will include a discussion on the updated Intimate Partner Violence Prevention Research Priorities. The closed session of the meeting will focus on the Secondary Peer Review of extramural research grant applications received in response to one (1) Notice of Funding Opportunity: RFA-CE-24-001—"Grants for Injury Control Research Centers." Agenda items are subject to change as priorities dictate.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2023-16104 Filed 7-28-23; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Solicitation of Nominations for Appointment to CDC's Advisory Committee to the Director Data and Surveillance Workgroup

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), is seeking nominations for membership on the Advisory Committee to the Director Data and Surveillance Workgroup (DSW). The DSW consists of approximately 15 members who are experts in fields associated with public health science and practice; policy development, analysis, and implementation; and surveillance and informatics.

**DATES:** Nominations for membership on the DSW must be received no later than August 30, 2023. Late nominations will not be considered for membership.

**ADDRESSES:** All nominations (cover letters and curriculum vitae) should be emailed to [DSWACD@cdc.gov](mailto:DSWACD@cdc.gov) with the

subject line: "Nomination for CDC ACD DSW Workgroup."

**FOR FURTHER INFORMATION CONTACT:** Agnes Warner, MPA, Office of Public Health Data, Surveillance, and Technology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H21-10, Atlanta, Georgia 30329-4027. Telephone: (404) 639-3372; Email: [DSWACD@cdc.gov](mailto:DSWACD@cdc.gov).

**SUPPLEMENTARY INFORMATION:**

*Background:* The purpose of the Advisory Committee to the Director, Centers for Disease Control and Prevention (ACD, CDC) is to (1) make recommendations to the Director regarding ways to prioritize the activities of the agency in alignment with the CDC Strategic Plan required under section 305(c); H.R. 2617-1252; (2) advise on ways to achieve or improve performance metrics in relation to the CDC Strategic Plan, and other relevant metrics, as appropriate; (3) provide advice and recommendations on the development of the Strategic Plan, and any subsequent updates, as appropriate; (4) advise on grants, cooperative agreements, contracts, or other transactions, as applicable; (5) provide other advice to the Director, as requested, to fulfill duties under sections 301 and 311; and (6) appoint subcommittees. The ACD, CDC consists of up to 15 non-federal members, including the Chair, knowledgeable in areas pertinent to the CDC mission, such as health policy, public health, global health, preparedness, preventive medicine, the faith-based and community-based sector, and allied fields.

*Purpose:* The purpose of the ACD, CDC Data and Surveillance Workgroup (DSW) is to provide input to the Committee on agency-wide activities related to the scope and implementation of CDC's data modernization strategy across the agency, ultimately playing a key role in the agency's work with public health, healthcare, and academic and private sector partners and with the promotion of equity. The DSW membership consists of approximately 15 members. It is co-chaired by two current ACD, CDC Special Government Employees. The DSW co-chairs will present their findings, observations, and work products at one or more ACD, CDC meetings for discussion, deliberation, and decisions (final recommendations to CDC).

*Nomination Criteria:* DSW members will serve terms ranging from six months to one year and be required to attend DSW meetings approximately 1-2 times per month (virtually or in person), and contribute time in between

meetings for research, consultation, discussion, and writing assignments.

Nominations are being sought for individuals who have the expertise and qualifications necessary to contribute to the accomplishments of the committee's/workgroup's objectives. Nominees will be selected based on expertise in the fields of public health science and practice; public health preparedness and response; public health policy development, analysis, and implementation; public health surveillance and informatics; artificial intelligence; data analysis, data science, and forecasting; health information technology; and healthcare delivery from jurisdictional government agencies, non-government organizations, academia, and the private sector. To ensure a diverse workgroup composition, nominees with front line and field experience at the local, state, tribal, and territorial levels are encouraged to apply. This includes nominees with experience working for, and with, community-based organizations and other non-profit organizations. Federal employees will not be considered for membership. Selection of members is based on candidates' qualifications to contribute to the accomplishment of the DSW's objectives.

HHS policy stipulates that membership be balanced in terms of points of view represented and the workgroup's function. Appointments shall be made without discrimination based on age, race, ethnicity, gender, sexual orientation, gender identity, HIV status, disability, and cultural, religious, or socioeconomic status. Nominees must be U.S. citizens. Current participation on federal workgroups or prior experience serving on a federal advisory committee does not disqualify a candidate; however, HHS policy is to avoid excessive individual service on advisory committees and multiple committee memberships. Interested candidates should submit the following items:

- A one-half to one-page cover letter that includes your understanding of, and commitment to, the time and work necessary; one to two sentences on your background and experience; and one to two sentences on the skills/perspective you would bring to the DSW.

- Current curriculum vitae which highlights the experience and work history being sought relevant to the criteria set forth above, including complete contact information (telephone numbers, mailing address, email address).

Nominations may be submitted by the candidate or by the person/organization recommending the candidate.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-16102 Filed 7-28-23; 8:45 am]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**National Center for Health Statistics, ICD-10 Coordination and Maintenance Committee**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, announces the following meeting of the ICD-10 Coordination and Maintenance (C&M) Committee. This meeting is open to the public, limited only by the number of audio lines available. Online Registration is required.

**DATES:** The meeting will be held on September 12, 2023, from 9 a.m. to 5 p.m., EDT, and September 13, 2023, from 9 a.m. to 5 p.m., EDT.

**ADDRESSES:** This is a virtual meeting. Register in advance at [https://cms.zoomgov.com/webinar/register/WN\\_IWLKuwKzQU6jdvcdvXhdA](https://cms.zoomgov.com/webinar/register/WN_IWLKuwKzQU6jdvcdvXhdA). After registering, you will receive a confirmation email containing information about joining the meeting. Further information will be provided on each of the respective web pages when it becomes available. For CDC, NCHS: [https://www.cdc.gov/nchs/icd/icd10cm\\_maintenance.htm](https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm). For the Centers for Medicare & Medicaid Services, Department of Health and Human Services: <https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials>.

**FOR FURTHER INFORMATION CONTACT:**

Traci Ramirez, Medical Classification Specialist, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Hyattsville, Maryland 20782-2064. Telephone: (301) 458-4454; Email: [TRamirez@cdc.gov](mailto:TRamirez@cdc.gov).

**SUPPLEMENTARY INFORMATION:**

*Purpose:* The ICD-10 Coordination and Maintenance (C&M) Committee is a public forum for the presentation of proposed modifications to the International Classification of Diseases, Tenth Revision, Clinical Modification (CM) and ICD-10 Procedure Coding System (PCS).

*Matters to be Considered:* The tentative agenda will include discussions on the ICD-10-CM and ICD-10-PCS topics listed below. Agenda items are subject to change as priorities dictate. Please refer to the posted agenda for updates one month prior to the meeting.

ICD-10-PCS Topics:

1. Administration of Iodine (131I) Apamistamab \*\*
2. Irreversible Electroporation for Cardiac Ablation \*\*
3. Computer-aided Anesthesia and Oxygen Delivery System \*\*\*
4. Sub-epidermal Moisture Sensor \*\*
5. Insertion of Palladium-103 Radioactive Implant \*
6. Implantation of Bone Void Filler \*\*\*
7. Section X Updates
8. Addenda and Key Updates \*

\* Request is for an April 1, 2024, implementation date.

\*\* Request is for an April 1, 2024, implementation date, and the requestor intends to submit a new technology add-on payment (NTAP) application for FY 2025 consideration.

\*\*\* Requestor intends to submit an NTAP application for FY 2025 consideration.

Presentations for procedure code requests are conducted by both the requestor and the Centers for Medicare & Medicaid Services (CMS) during the C&M Committee meeting. Discussion from the requestor generally focuses on the clinical issues for the procedure or technology, followed by the proposed coding options from a CMS analyst. Topics presented may also include requests for new procedure codes that relate to a new technology add-on payment (NTAP) policy request.

CMS has modified the approach for presenting the new NTAP-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent. For the September 12-13, 2023, ICD-10 C&M Committee meeting, consistent with the

requirements of section 1886(d)(5)(K)(iii) of the Social Security Act, applicants submitted requests to create a unique procedure code to describe the administration of a therapeutic agent, such as the option to create a new code in Section X within the ICD-10-PCS procedure code classification. CMS will initially display only those meeting materials associated with the NTAP-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent on the CMS website in August 2023 at: <https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials>.

The NTAP-related ICD-10-PCS procedure code request that involves the administration of a therapeutic agent is: Administration of Iodine (131I) Apamistamab \*\*

\*\* Request is for an April 1, 2024, implementation date, and the requestor intends to submit an NTAP application for FY 2025 consideration.

This topic will not be presented during the September 12-13, 2023, meeting. CMS will solicit public comments regarding any clinical questions or coding options included for this procedure code topic in advance of the meeting continuing through the end of the respective public comment periods. Members of the public should send any questions or comments to the CMS mailbox at: [ICDProcedureCodeRequest@cms.hhs.gov](mailto:ICDProcedureCodeRequest@cms.hhs.gov).

CMS intends to post a question-and-answer document in advance of the meeting to address any clinical or coding questions that members of the public may have submitted. Following the conclusion of the meeting, CMS will post an updated question-and-answer document to address any additional clinical or coding questions that members of the public may have submitted during the meeting that CMS was not able to address or that were submitted after the meeting.

The NTAP-related ICD-10-PCS procedure code requests that do not involve the administration of a therapeutic agent and all non-NTAP-related procedure code requests will continue to be presented during the virtual meeting on September 12, 2023, consistent with the standard meeting process.

CMS will make all meeting materials and related documents available at: <https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials>. Any inquiries related to the procedure code topics scheduled for the September 12-13, 2023, ICD-10 C&M Committee meeting that are under consideration for